NAGE is the ticker symbol for Niagen Bioscience, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks NAGE with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is NAGE a good stock to buy?

13F Pro's AI ranking engine scores NAGE at 52.9/100, ranked #1,443 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for NAGE is available at https://13fpro.ai/company/NAGE. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source NAGE data?

All Niagen Bioscience, Inc. fundamentals and ownership data come directly from SEC EDGAR. Niagen Bioscience, Inc. files with the SEC under CIK 1386570. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Niagen Bioscience, Inc. NAGE

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #1,443 of 2,925TOP 50%

Why it scores 53 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$29.79M

Quarter to Jun 30

Net income

$963.0K

Quarter to Jun 30

Operating margin

2.4%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$102.06M total

BlackRock, Inc.

$13.35M+8.1%

SteelPeak Wealth, LLC

$11.17M+3.8%

VANGUARD CAPITAL MANAGEMENT LLC

$6.85M-0.1%

Tieton Capital Management, LLC

$6.41M-1.0%

Qube Research & Technologies Ltd

$5.18M-5.2%

GEODE CAPITAL MANAGEMENT, LLC

$4.72M+9.9%

UBS Group AG

$4.09M-8.7%

GOLDMAN SACHS GROUP INC

$4.03M+0.9%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$3.74M-50.8%

VANGUARD PORTFOLIO MANAGEMENT LLC

$3.72M-4.5%

STATE STREET CORP

$3.45M-0.2%

RENAISSANCE TECHNOLOGIES LLC

$2.10M-50.4%

CITADEL ADVISORS LLC

$2.01M+18.8%

DIMENSIONAL FUND ADVISORS LP

$1.93M-43.5%

MORGAN STANLEY

$1.61M+32.5%

VICTORY CAPITAL MANAGEMENT INC

$1.51M+11.3%

AQR CAPITAL MANAGEMENT LLC

$1.51M-54.2%

SEI INVESTMENTS CO

$1.51M-51.4%

NORTHERN TRUST CORP

$1.49M+17.8%

Connor, Clark & Lunn Investment Management Ltd.

$1.46M-21.3%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$1.38M-3.5%

VANGUARD FIDUCIARY TRUST CO

$1.28M+6.9%

PANAGORA ASSET MANAGEMENT INC

$1.11M+96.2%

JPMORGAN CHASE & CO

$1.10M+2.0%

JACOBS LEVY EQUITY MANAGEMENT, INC

$1.04MNew

See all 140 institutional holders →

What's Driving NAGE's Business? Latest 10-Q Breakdown

20/20 datapoints verified

AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue declined 4% YoY to $29.8M as Ingredients segment weakness and divestiture of Analytical Reference Standards business offset Consumer Products growth.

Biggest Revenue Drivers

Consumer Products$24.2M+6% YoY

Tru Niagen e-commerce channel grew ~$2.5M; offset by $2.3M decline in A.S. Watson Group sales; cross-border China sales increased ~$1.0M.

Ingredients$5.4M-29% YoY

Food-grade Niagen sales declined $1.1M due to softer downstream demand; pharmaceutical-grade sales fell $1.0M from reduced partner purchasing.

Biggest Revenue Drivers

Total revenue: $29.8M-4% YoY

Consumer Products$24.2M+6% YoY

Tru Niagen e-commerce channel grew ~$2.5M; offset by $2.3M decline in A.S. Watson Group sales; cross-border China sales increased ~$1.0M.

Ingredients$5.4M-29% YoY

Food-grade Niagen sales declined $1.1M due to softer downstream demand; pharmaceutical-grade sales fell $1.0M from reduced partner purchasing.

Analytical Reference Standards and Services$0MN/A

Business divested February 2026; Q2 2026 reflects only partial-period operations prior to sale.

Corporate and Other$0.2MN/A

Transition services revenue from post-divestiture agreement with buyer.

Largest Expense Items

Sales and Marketing$10.1M+23% YoY

Higher advertising and marketing spend for brand growth and customer acquisition; expansion of marketing organization personnel costs.

Cost of Sales$10.5M-4% YoY

Consumer Products gross margin improved 40 bps from e-commerce mix shift; Ingredients margin declined 720 bps due to unfavorable product mix and pricing concessions.

General and Administrative$7.0M-4% YoY

Lower royalties and professional fees offset by higher share-based compensation.

Research and Development$1.5M-3% YoY

Pharmaceuticals R&D increased 29% from CRO agreement for development programs; Niagen-allocated R&D to Consumer Products and Ingredients remained flat.

Margins: Gross margin declined 50 bps YoY to 64.8% due to unfavorable product mix in Ingredients (higher food-grade, lower pharmaceutical-grade sales) and pricing concessions to support commercial relationships, partially offset by e-commerce channel growth in Consumer Products. Operating margin compressed significantly to 2.4% from 10.2% YoY due to 760 bps increase in sales and marketing expense as percentage of revenue.

Watch Items from the Filing

Ingredients segment revenue declined 29% YoY; Company attributed decline to NMN competition following FDA's September 2025 determination and customer mix shift, creating significant margin pressure.
Two major customers (Customer C at 26.1% and Customer B at ~23.0% of trade receivables as of June 30, 2026) represent 37.2% of total outstanding receivables, creating collection and revenue concentration risk.
Pending litigation: Elysium Health appeals $9.2M attorneys' fees judgment (with post-judgment interest estimated at ~$10.4M through appeal); Federal Circuit oral arguments held July 9, 2026 with no ruling yet.
Two putative class action complaints filed May–June 2026 in California federal courts challenging Tru Niagen advertising claims; consolidated proceeding with amended complaint due August 14, 2026; no accrual recorded as early stage.
Company operates under sole-source NRC supply agreement with W.R. Grace through April 30, 2029 with ~$20.5M minimum purchase obligation through June 30, 2027; Grace holds crystalline NRC patents limiting alternative sourcing.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/NAGE

Earnings Per Share

13fpro.ai/company/NAGE

Loading ratio trend…

Niagen Bioscience, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$129.4M	$17.4M	12.6%
FY 2024	10-K	$99.6M	$8.6M	7.8%
FY 2023	10-K	$83.6M	$-4.9M	-6.7%
FY 2022	10-K	$72.0M	$-16.5M	-25.9%
FY 2021	10-K	$67.4M	$-27.1M	-40.1%
FY 2020	10-K	$59.3M	$-19.9M	-33.5%

About Niagen Bioscience, Inc. (NAGE): stock profile, AI score and financials

Niagen Bioscience, Inc. (NAGE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NAGE at 52.9/100 on a composite quality score built from its SEC filings, placing it at rank #1,443 of 2,925 stocks — the top half of the AI-ranked universe. NAGE scores in the top quartile across balance sheet strength (94.0), revenue growth (83.2). Areas of concern include institutional flow (6.0) and revenue scale (19.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Niagen Bioscience, Inc. reports quarterly revenue of $29.8M, net income of $963.0K, an operating margin of 2.4%. Top institutional holders of NAGE by reported 13-F value include BlackRock, SteelPeak Wealth, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NAGE trades on the Nasdaq exchange and files with the SEC under CIK 1386570. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NAGE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Niagen Bioscience, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1386570 →

Niagen Bioscience, Inc. NAGE

Top Institutional Holders

What's Driving NAGE's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

NAGE key financials by period

NAGE insiders

About Niagen Bioscience, Inc. (NAGE): stock profile, AI score and financials

Niagen Bioscience, Inc. NAGE

Top Institutional Holders

What's Driving NAGE's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

NAGE key financials by period

Companies similar to NAGE

NAGE insiders

About Niagen Bioscience, Inc. (NAGE): stock profile, AI score and financials